Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health, Inc. (HIMS) reported that Chief Medical Officer Patrick Harrison Carroll exercised and settled several Restricted Stock Unit (RSU) awards into a total of 26,187 shares of Class A Common Stock on 2026-08-14 at a conversion price of $0.00 per share. The company withheld 10,201 shares at $28.15 per share to cover tax withholding obligations related to these vestings. Footnotes state that one RSU grant was issued under the issuer’s Director Compensation Policy in lieu of $7,912 of cash fees at a grant price of $30.40, and that other RSU blocks vest over four years based on continued service.
Hims & Hers Health, Inc. (HIMS) reported insider equity activity by CEO and 10% owner Andrew Dudum on 2026-08-14. Several tranches of Restricted Stock Units (RSUs) were vested and converted into 154,993 shares of Class A Common Stock, reflecting equity compensation. Of these, 78,859 shares were withheld by the issuer at $28.15 per share to satisfy tax withholding obligations, rather than sold in the market. The RSU grants vest over four-year service-based schedules in substantially equal quarterly installments beginning on various dates from June 15, 2023 through June 15, 2026. Following these transactions, Dudum continues to hold substantial indirect Class A Common Stock positions through multiple family and GRAT trusts, with individual post-transaction balances reported for each trust.
Hims & Hers Health, Inc. (HIMS) reported that Chief Operating Officer Michael Chi had multiple restricted stock unit (RSU) awards vest on 2026-08-14, converting into 86,265 shares of Class A Common Stock at a price of $0.00 per share. In connection with this vesting and settlement, the company withheld 47,702 shares at a price of $28.15 per share to satisfy tax withholding obligations. The RSU grants vest over four years in substantially equal quarterly installments, with different grants beginning to vest on quarterly dates starting between December 15, 2022 and June 15, 2026.
Hims & Hers Health, Inc. (HIMS) reported that its Chief Financial Officer, Oluyemi Okupe, executed several equity transactions. On August 17, 2026, he exercised 9,388 stock options for Class A Common Stock at an exercise price of $5.01 per share, then sold 9,388 shares of Class A Common Stock at a weighted average price of $27.8869 per share pursuant to a Rule 10b5-1 trading plan. The underlying stock option award is fully vested, with 85,810 options reported as held directly after the exercise.
On August 14, 2026, multiple tranches of Restricted Stock Units (RSUs) vested and converted into an aggregate of 71,616 shares of Class A Common Stock, reflecting several service-based RSU awards that vest in substantially equal quarterly installments over four-year periods starting on June 15 of 2023, 2024, 2025, and 2026. In connection with this vesting, 36,437 shares of Class A Common Stock were withheld by the company at $28.15 per share to cover tax withholding obligations. Earlier, on June 18, 2026, Okupe sold 55,383 shares of Class A Common Stock at a weighted average price of $35.09 per share, also under the same Rule 10b5-1 trading plan.
Hims & Hers Health, Inc. (HIMS) reported that Chief Policy Officer and director Deborah M. Autor had 32,920 Restricted Stock Units (RSUs) vest and convert into an equal number of shares of Class A Common Stock on August 14, 2026. Of these, 16,147 shares were withheld by the company at $28.15 per share to cover tax withholding obligations. After this RSU exercise and related tax withholding, she reported direct holdings of 427,953 RSUs, which continue to vest quarterly over a four-year service-based schedule beginning March 15, 2026.
Hims & Hers Health, Inc. (HIMS) director David B. Wells reported equity compensation activity involving 778 Restricted Stock Units (RSUs) on August 14, 2026. Each RSU represents a contingent right to receive one share of Class A Common Stock, granted under the company’s Director Compensation Policy in lieu of a cash retainer. The filing notes that the RSUs, calculated from $23,760 of foregone cash fees at a $30.40 grant price, will vest in full on the company’s next quarterly vesting date. Following the reported transactions, Wells is shown with 229,808 shares of Class A Common Stock held directly.
Hims & Hers Health, Inc. reported equity compensation activity by CTO Mohamed Elshenawy involving the vesting and settlement of restricted stock units (RSUs) into Class A Common Stock. On 2026-08-14, RSUs covering 188,285 shares were exercised/converted into an equal number of Class A shares. In connection with this vesting, 95,798 shares of Class A Common Stock were withheld by the company at $28.15 per share to satisfy tax withholding obligations. The RSU awards are subject to service-based vesting over 3- and 4-year periods, with initial and subsequent vesting occurring on the company’s quarterly vesting dates beginning June 15, 2026.
Hims & Hers Health, Inc. (HIMS) reported that officer Irene Becklund (PAO) had Restricted Stock Units (RSUs) vest and convert into 13,685 shares of Class A Common Stock on 2026-08-14, pursuant to multi‑year, service-based, quarterly vesting schedules. In connection with this vesting, 6,490 shares of Class A Common Stock were withheld by the company at $28.15 per share to cover tax withholding obligations. The filing does not report updated post-transaction share holdings.
Hims & Hers Health, Inc. (HIMS) director Christopher D. Payne reported an exercise of 545 Restricted Stock Units (RSUs) into 545 shares of Class A common stock on 2026-08-14, leaving him with 34,863 shares held directly and 110,000 shares held indirectly through The Payne Family Trust. The RSUs represent a contingent right to receive one share of Class A common stock per unit and were issued under the company’s Director Compensation Policy in lieu of the second-quarter 2026 cash retainer fee, with the $16,598 foregone fees divided by a $30.40 grant price to determine the grant amount; the RSUs will vest in full on the company’s next quarterly vesting date.
Hims & Hers Health, Inc. (HIMS) is the issuer in a planned secondary sale by stockholder Deborah M. Autor under Rule 144. A notice was filed for the potential sale of 16,773 Class A shares through Fidelity Brokerage Services LLC. The filing lists an aggregate market value of $467,128.05 for these shares and total Class A shares outstanding of 224,935,790. The shares relate to restricted stock vesting designated as compensation, with a noted proposed sale date of August 18, 2026 on the NYSE.